Compare VITL & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VITL | URGN |
|---|---|---|
| Founded | 2007 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 944.3M | 922.1M |
| IPO Year | 2020 | 2016 |
| Metric | VITL | URGN |
|---|---|---|
| Price | $20.04 | $18.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | ★ $42.56 | $29.29 |
| AVG Volume (30 Days) | ★ 2.1M | 800.4K |
| Earning Date | 01-01-0001 | 06-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.03 | N/A |
| EPS | ★ 1.44 | N/A |
| Revenue | ★ $759,444,000.00 | $1,128,000.00 |
| Revenue This Year | $26.07 | $119.37 |
| Revenue Next Year | $20.95 | $64.79 |
| P/E Ratio | $13.90 | ★ N/A |
| Revenue Growth | ★ 25.26 | N/A |
| 52 Week Low | $19.75 | $3.42 |
| 52 Week High | $53.13 | $30.00 |
| Indicator | VITL | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 23.17 | 42.05 |
| Support Level | N/A | $18.65 |
| Resistance Level | $31.02 | $20.44 |
| Average True Range (ATR) | 1.24 | 1.63 |
| MACD | -0.58 | -0.17 |
| Stochastic Oscillator | 3.04 | 25.17 |
Vital Farms Inc is an ethical food company. The company retails pasture-raised eggs and butter. Its products include Pasture-Raised Eggs and Pasture-Raised Butter & Ghee. The company's purpose is rooted in a commitment to Conscious Capitalism, which prioritizes the long-term benefits of its stakeholders (farmers and suppliers, customers and consumers, communities and the environment, employees, and stockholders).
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.